Marksans Pharma Ltd Technical Momentum Shifts Amid Market Volatility
NiveshIQ
NSE: MARKSANS · Pharma
Marksans Pharma Ltd.
₹259.45▲ ₹2.80 (+1.09%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on MARKSANS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Marksans Pharma Ltd.
Marksans Pharma Limited is a leading Indian pharmaceutical company with a diversified product portfolio across various therapeutic areas, including pain management, cardiovascular, and anti-diabetic. The company offers a wide range of products, including tablets, capsules, oral liquids, and ointments, which are sold to supermarkets, high street retailers, pharmacy chains, and wholesalers globally. With a strong presence in the US, North America, Europe, and other international markets, Marksans Pharma has established itself as a reliable player in the pharmaceutical industry. The company's recent financial performance has been impressive, with a 64% surge in profit in Q4 FY26, driven by a strong revenue growth. Marksans Pharma's valuation concerns persist, but the company's broad-based tec
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,177 Cr +17.50% | ₹2,623 Cr +20.50% | ₹2,951 Cr +12.50% |
| EBITDA Margin | 21.08% | 20.63% | 23.16% |
| Net Profit | ₹315.00 Cr +18.90% | ₹383.00 Cr +21.60% | ₹420.06 Cr +9.70% |
| EPS | ₹6.93 | ₹8.40 | ₹9.22 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Marksans Pharma Ltd Valuation Adjusted Amid Price Correction and Sector Comparison
Marksans Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals
🔒
+ 3 more stories about Marksans Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹856 Cr, PAT ₹149 Cr, EPS ₹3.27, EBITDA margin 26.9%. Growth context: revenue YoY +20.9%, PAT YoY +63.8%, revenue QoQ +13.5%, PAT QoQ +30.7%. Street verdict: inline, revenue surprise +2.4%, PAT surprise -0.3%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new product launches and ma...
FY26 (last completed FY): revenue ₹2, 951 Cr, PAT ₹420 Cr, EBITDA margin 23.2%, EPS ₹9.22. Year-on-year: revenue YoY +12...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for MARKSANS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track MARKSANS alongside your other holdings
Unlock full MARKSANS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Marksans Pharma Ltd.?
NiveshIQ detects active intelligence signals for Marksans Pharma Ltd. (MARKSANS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Marksans Pharma Ltd.?
Marksans Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹1,129,601.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.